| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AJS-4 AI consultation for NGS results
|
Nishihara, Hiroshi
|
|
|
32 |
S4 |
p. S232
|
artikel
|
| 2 |
AJS-5 Forefront challenge in the SCRUM-Japan utilizing Artificial Intelligence (AI) – Virtual Sequencing (VSQ) and QA Commons (QAC) projects and beyond
|
Yoshino, Takayuki
|
|
|
32 |
S4 |
p. S232
|
artikel
|
| 3 |
AJS-1 Identifying subgroups at high-risk of ICI associated cardiac adverse events: An approach using topological data analysis
|
Heilbroner, Samuel
|
|
|
32 |
S4 |
p. S232
|
artikel
|
| 4 |
AJS-3 Incorporating AI into oncology practice: Opportunities and challenges
|
Burris, Howard A.
|
|
|
32 |
S4 |
p. S232
|
artikel
|
| 5 |
APJS-3 The Australian experience of commercial CAR-T implementation
|
Dickinson, Michael
|
|
|
32 |
S4 |
p. S233
|
artikel
|
| 6 |
APJS-2 Updates in research for CAR-T therapy in China
|
Li, Zonghai
|
|
|
32 |
S4 |
p. S233
|
artikel
|
| 7 |
Disclaimer
|
|
|
|
32 |
S4 |
p. iii
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
32 |
S4 |
p. i
|
artikel
|
| 9 |
EJS-1 Clinical utility of analysing ctDNA in patients with metastatic colorectal cancer
|
Tabernero, Josep
|
|
|
32 |
S4 |
p. S230
|
artikel
|
| 10 |
EJS-5 ctDNA&beyond in urological tumors
|
Akamatsu, Shusuke
|
|
|
32 |
S4 |
p. S230
|
artikel
|
| 11 |
EL7 Categories and characteristics of molecular targeting agents
|
Sasaki, Jiichiro
|
|
|
32 |
S4 |
p. S277
|
artikel
|
| 12 |
GL-1 Clinical recommendations on the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair (dMMR) tumors
|
Mishima, Saori
|
|
|
32 |
S4 |
p. S283
|
artikel
|
| 13 |
GL-2 Clinical recommendations on the diagnosis and use of TRK inhibitors in adult and pediatric patients with NTRK fusion-positive advanced solid tumors
|
Nito, Yoichi
|
|
|
32 |
S4 |
p. S283
|
artikel
|
| 14 |
Journal Information
|
|
|
|
32 |
S4 |
p. ii
|
artikel
|
| 15 |
JS6-3 Cancer treatment support for patients who have difficulties in daily life
|
Hayashi, Eriko
|
|
|
32 |
S4 |
p. S238
|
artikel
|
| 16 |
JS4-1 Current issues and situation of AYA cancer in Japan
|
Shimizu, Chikako
|
|
|
32 |
S4 |
p. S236
|
artikel
|
| 17 |
JS5-3 Current status and core measures of cancer-associated thromboembolism
|
Imamura, Yoshinori
|
|
|
32 |
S4 |
p. S237
|
artikel
|
| 18 |
JS2-3 Current status of concurrent radiotherapy and immunotherapy
|
Imamura, Yoshinori
|
|
|
32 |
S4 |
p. S234
|
artikel
|
| 19 |
JS3-4 Involvement of genetic counseling on comprehensive genomic profiling in cancer patients
|
Oseto, Kumiko
|
|
|
32 |
S4 |
p. S235
|
artikel
|
| 20 |
JS5-5 Onco-cardiology: Collaboration and task sharing for oncologist and cardiologist
|
Mukai, Mikio
|
|
|
32 |
S4 |
p. S237
|
artikel
|
| 21 |
JS2-1 The basics of immuno-radiotherapy
|
Suzuki, Yoshiyuki
|
|
|
32 |
S4 |
p. S234
|
artikel
|
| 22 |
JS7-4 The impact of surgical treatment on sarcomas using propensity score methods
|
Takenaka, Satoshi
|
|
|
32 |
S4 |
p. S239
|
artikel
|
| 23 |
MC-3 Introduce career support, lifework management system and commitment to employees' satisfaction at a foreign pharmaceutical manufacturer
|
Ohki, Emiko
|
|
|
32 |
S4 |
p. S281
|
artikel
|
| 24 |
ME19 Future directions for the treatment of head and neck cancer
|
Cohen, Ezra
|
|
|
32 |
S4 |
p. S280
|
artikel
|
| 25 |
ME3 State of the art management of metastatic urothelial cancer in 2021
|
Kanesvaran, Ravindran
|
|
|
32 |
S4 |
p. S279
|
artikel
|
| 26 |
ME1 Why is biliary tract cancer special?
|
Bridgewater, John
|
|
|
32 |
S4 |
p. S278
|
artikel
|
| 27 |
MO1-5 A combined tissue microRNA panel is a predictive biomarker for colorectal cancer recurrence
|
Ng, Lui
|
|
|
32 |
S4 |
p. S294
|
artikel
|
| 28 |
MO4-5 A multicenter retrospective study of Oncomine Dx Target Test multi-CDx system for genetic profiling of NSCLC: WJOG13019L
|
Ito, Kentaro
|
|
|
32 |
S4 |
p. S297
|
artikel
|
| 29 |
MO36-4 A multi-institutional, single-arm phase II study of pembrolizumab plus amrubicin in relapsed small cell lung cancer
|
Haratani, Koji
|
|
|
32 |
S4 |
p. S322
|
artikel
|
| 30 |
MO16-5 Analysis of employment counseling for advanced cancer patients undergoing cancer drug therapy
|
Kaku, Sawako
|
|
|
32 |
S4 |
p. S307
|
artikel
|
| 31 |
MO5-4 Angiogenesis-related factors associated with nivolumab efficacy after ramucirumab therapy in advanced gastric cancer
|
Matsubara, Yuki
|
|
|
32 |
S4 |
p. S298
|
artikel
|
| 32 |
MO20-6 A prospective study comparing metabolic tools on PET scan with Mandard grading following NACT in SCC of esophagus
|
Kumar, Naveen
|
|
|
32 |
S4 |
p. S311
|
artikel
|
| 33 |
MO32-4 A real-world multicentre retrospective study of low-dose apatinib for HER2-negative metastatic breast cancer
|
Zeng, Tianyu
|
|
|
32 |
S4 |
p. S319
|
artikel
|
| 34 |
MO12-3 Association between relative dose intensity and prognosis in patients aged 80 years and older with DLBCL
|
Lee, Shin
|
|
|
32 |
S4 |
p. S304
|
artikel
|
| 35 |
MO10-2 Association of pre-existing interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with non-lung cancers
|
Shimoji, Kiyofumi
|
|
|
32 |
S4 |
p. S302
|
artikel
|
| 36 |
MO33-8 A systematic review of chemotherapy for breast cancer patients during the COVID-19 pandemic era
|
Widjaja, Devita
|
|
|
32 |
S4 |
p. S321
|
artikel
|
| 37 |
MO22-5 Burden of illness & real-world treatment patterns in patients with metastatic synovial sarcoma (mSS) in China & Japan
|
Patel, Nashita
|
|
|
32 |
S4 |
p. S311
|
artikel
|
| 38 |
MO13-4 Case series of cancer of unknown primary site in Toyama University Hospital
|
Kaihara, Takeshi
|
|
|
32 |
S4 |
p. S305
|
artikel
|
| 39 |
MO28-1 Change in status of medical oncology in Japan over a seven-year period
|
Arai, Makoto
|
|
|
32 |
S4 |
p. S315
|
artikel
|
| 40 |
MO5-1 Characteristics of immune-related adverse events in patients with advanced esophageal cancer treated with nivolumab
|
Nakada, Naokatsu
|
|
|
32 |
S4 |
p. S298
|
artikel
|
| 41 |
MO13-1 Characteristics of mucosal melanoma in comparison with cutaneous melanoma: Analysis of real-world data
|
Namba, Masashi
|
|
|
32 |
S4 |
p. S304
|
artikel
|
| 42 |
MO18-2 Characterization of URST5 as a potential biomarker and therapeutic target for oral cancer
|
Tsevegjav, Bayarbat
|
|
|
32 |
S4 |
p. S308
|
artikel
|
| 43 |
MO33-3 Clinical characteristics and outcomes of cancer patients with COVID-19: A study in a single center in the Philippines
|
Gilda P Pandy, Jessa
|
|
|
32 |
S4 |
p. S320
|
artikel
|
| 44 |
MO13-5 Clinical features and prognosis of patients with unresectable locally advanced or metastatic olfactory neuroblastoma
|
Furukawa, Haruhi
|
|
|
32 |
S4 |
p. S305
|
artikel
|
| 45 |
MO31-7 Clinical genome sequencing in pancreatic ductal adenocarcinoma – Comprehensive gene panel versus whole-exome sequencing
|
Tezuka, Shun
|
|
|
32 |
S4 |
p. S319
|
artikel
|
| 46 |
MO9-5 Clinical implementation of cancer genomic medicine using gene profiling test under national health insurance in Japan
|
Fukada, Ippei
|
|
|
32 |
S4 |
p. S301
|
artikel
|
| 47 |
MO27-3 Clinical outcomes of metastasis-directed radiation therapy (MDRT) for oligometastatic prostate cancer
|
Tabata, Ken-ichi
|
|
|
32 |
S4 |
p. S315
|
artikel
|
| 48 |
MO27-6 Clinical significance of urinary cell-free DNA in urothelial cancer
|
Fujita, Kazutoshi
|
|
|
32 |
S4 |
p. S315
|
artikel
|
| 49 |
MO38-3 Clinical update with genomic analyses in expansion part of phase 1 study of selective FGFR inhibitor E7090
|
Ueno, Makoto
|
|
|
32 |
S4 |
p. S324
|
artikel
|
| 50 |
MO16-6 Clinicopathologic features and survival of Filipino women with triple-negative breast cancer: A single-center experience
|
Ando, Mark M.
|
|
|
32 |
S4 |
p. S307
|
artikel
|
| 51 |
MO18-7 Combinatorial treatments of aspirin with glutaminolysis-targeting agents against PIK3CA-mutated colorectal cancer cells
|
Boku, Shogen
|
|
|
32 |
S4 |
p. S309
|
artikel
|
| 52 |
MO27-1 Correlation between immune-related adverse events and prognosis in renal cell carcinoma patients treated with nivolumab
|
Kato, Taigo
|
|
|
32 |
S4 |
p. S314
|
artikel
|
| 53 |
MO13-3 Dabrafenib and trametinib treatment for patients with anaplastic thyroid cancer
|
Ito, Tokiko
|
|
|
32 |
S4 |
p. S305
|
artikel
|
| 54 |
MO23-1 Detection of hematological malignancies using N-NOSE (Nematode-NOSE)
|
Nakamura, Shingen
|
|
|
32 |
S4 |
p. S312
|
artikel
|
| 55 |
MO9-8 Development of a data management system for comprehensive genomic profiling tests
|
Fukuyama, Keita
|
|
|
32 |
S4 |
p. S301
|
artikel
|
| 56 |
MO16-4 Development of a screening tool to determine support needs for Japanese adolescents and young adults with cancer
|
Hirayama, Takatoshi
|
|
|
32 |
S4 |
p. S307
|
artikel
|
| 57 |
MO38-5 Dipeptidyl peptidase-4 inhibitors and risk of gall bladder cancer in type 2 diabetes patients: A meta-analytic synthesis
|
Azharuddin, Md
|
|
|
32 |
S4 |
p. S324
|
artikel
|
| 58 |
MO11-1 Efficacy and safety of perioperative dose-dense chemotherapy for breast cancer patients, including elderly population
|
Ishiguro, Atsushi
|
|
|
32 |
S4 |
p. S303
|
artikel
|
| 59 |
MO4-7 Efficacy and safety with selpercatinib in patients with RET fusion+ NSCLC: Analysis by last prior systemic therapy
|
Goto, Koichi
|
|
|
32 |
S4 |
p. S297
|
artikel
|
| 60 |
MO37-5 Efficacy of liquid biopsy testing for comprehensive cancer genome profiling in 88 cases
|
Shibata, Nobuhiro
|
|
|
32 |
S4 |
p. S322
|
artikel
|
| 61 |
MO4-1 EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402
|
Yonesaka, Kimio
|
|
|
32 |
S4 |
p. S296
|
artikel
|
| 62 |
MO18-1 EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
|
Adachi, Yuta
|
|
|
32 |
S4 |
p. S307
|
artikel
|
| 63 |
MO18-5 Establishment of organoids derived from patients with advanced thoracic malignancies
|
Oyanagi, Jun
|
|
|
32 |
S4 |
p. S308
|
artikel
|
| 64 |
MO14-3 Establishment of patient derived organoids from resected primary lung cancer as an in vitro model for drug screening
|
Koga, Takamasa
|
|
|
32 |
S4 |
p. S306
|
artikel
|
| 65 |
MO34-3 Evaluation for penetration and usage of Japanese guidelines on febrile neutropenia among hematology-oncology physicians
|
Akiyama, Nobu
|
|
|
32 |
S4 |
p. S321
|
artikel
|
| 66 |
MO8-1 Examination of the usefulness of MeAIB PET for head and neck cancer
|
Komurasaki, Ayana
|
|
|
32 |
S4 |
p. S299
|
artikel
|
| 67 |
MO20-4 FOLFOX or FOLFOX plus radiation therapy for locally advanced or metastatic esophageal squamous cell carcinoma
|
Shiraishi, Kazuhiro
|
|
|
32 |
S4 |
p. S310
|
artikel
|
| 68 |
MO14-1 From mouse to human: Focused gene panel immunoprofiling
|
Marco, Develasco
|
|
|
32 |
S4 |
p. S305
|
artikel
|
| 69 |
MO1-2 Geriatric assessment and clinical outcomes for elderly colorectal cancer patients
|
Doi, Ayako
|
|
|
32 |
S4 |
p. S294
|
artikel
|
| 70 |
MO26-5 HGCSG 1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer
|
Sawada, Kentaro
|
|
|
32 |
S4 |
p. S314
|
artikel
|
| 71 |
MO32-7 High ALC, low NLR and PLR are associated with longer OS in patients with metastatic breast cancer treated with eribulin
|
Matsuura, Kazuo
|
|
|
32 |
S4 |
p. S319
|
artikel
|
| 72 |
MO37-1 Identification and evaluation of a serum microRNA molecular diagnostic method for colorectal polyp patients
|
Ng, Lui
|
|
|
32 |
S4 |
p. S322
|
artikel
|
| 73 |
MO18-3 Identification of URST4 protein as a novel prognostic biomarker and therapeutic target for oral cancer
|
Zhu, Ming
|
|
|
32 |
S4 |
p. S308
|
artikel
|
| 74 |
MO3-4 Impact of baseline tumor size on overall survival in patients with RR-DTC treated with lenvatinib (SELECT)
|
Kiyota, Naomi
|
|
|
32 |
S4 |
p. S296
|
artikel
|
| 75 |
MO35-4 Impact of omitting fluorouracil from FOLFIRI plus bevacizumab in second-line treatment of metastatic colorectal cancer
|
Matsubara, Yuki
|
|
|
32 |
S4 |
p. S321
|
artikel
|
| 76 |
MO2-5 Impact of pre-treatment AXL expression on EGFR-TKI efficacy in EGFR-mutated non-small cell lung cancer patients
|
Yoshimura, Akihiro
|
|
|
32 |
S4 |
p. S295
|
artikel
|
| 77 |
MO28-3 Impacts of health information technology on the continuing health care from the perspectives of oncology patients
|
Lin, Wan-Shiuan
|
|
|
32 |
S4 |
p. S316
|
artikel
|
| 78 |
MO19-2 INSIGHT2: Tepotinib + osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
|
Morise, Masahiro
|
|
|
32 |
S4 |
p. S309
|
artikel
|
| 79 |
MO31-3 Intratumor microbiome analysis of pancreatic cancer by analyzing the fresh frozen tissues obtained by EUS-FNA
|
Nakano, Shintaro
|
|
|
32 |
S4 |
p. S318
|
artikel
|
| 80 |
MO37-3 Is bronchoscopic cytology pellets useful for oncomine comprehensive assay? – from the samples submitted to LC-SCRUM
|
Tachihara, Motoko
|
|
|
32 |
S4 |
p. S322
|
artikel
|
| 81 |
MO14-2 KRAS Q61H mutation evades the regulation of tyrosyl phosphorylation and renders cancer cells resistant to SHP2 inhibitor
|
Kano, Yoshihito
|
|
|
32 |
S4 |
p. S306
|
artikel
|
| 82 |
MO5-5 Lesion-level response to immune checkpoint inhibitor in patients with advanced gastric cancer and esophageal cancer
|
Motoo, Iori
|
|
|
32 |
S4 |
p. S299
|
artikel
|
| 83 |
MO37-6 Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L)
|
Kato, Terufumi
|
|
|
32 |
S4 |
p. S323
|
artikel
|
| 84 |
MO25-3 Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater
|
Tambo, Yuichi
|
|
|
32 |
S4 |
p. S313
|
artikel
|
| 85 |
MO1-1 Lymphocyte-C-reactive protein ratio as a prognostic marker in rectal cancer patients with neoadjuvant chemoradiotherapy
|
Okugawa, Yoshinaga
|
|
|
32 |
S4 |
p. S294
|
artikel
|
| 86 |
MO14-4 Machine learning-based clustering of scRNAseq data from normal lung tissue and application to lung cancer
|
Ikushima, Hiroaki
|
|
|
32 |
S4 |
p. S306
|
artikel
|
| 87 |
MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer
|
Oh, Do-Youn
|
|
|
32 |
S4 |
p. S319
|
artikel
|
| 88 |
MO38-2 Metallothionein-3: Potential therapeutic target for sorafenib resistance in hepatocellular carcinoma
|
Merlos Rodrigo, Miguel A.
|
|
|
32 |
S4 |
p. S323
|
artikel
|
| 89 |
MO28-4 Multi-disciplinary collaboration on gene panel testing and review of factors in cases of unsuitable for gene profiling
|
Takahama, Takayuki
|
|
|
32 |
S4 |
p. S316
|
artikel
|
| 90 |
MO5-3 Nivolumab monotherapy in 3rd-line treatment for HER2 positive or negative advanced gastric cancer
|
Kito, Yosuke
|
|
|
32 |
S4 |
p. S298
|
artikel
|
| 91 |
MO29-2 Osimertinib for RT-naïve CNS metastasis of EGFRm NSCLC: pll OCEAN study (LOGIK 1603/WJOG 9116L), part of T790M cohort
|
Chibana, Kenji
|
|
|
32 |
S4 |
p. S316
|
artikel
|
| 92 |
MO4-4 Osimertinib is associated with type II cancer therapy-related cardiac dysfunction
|
Kunimasa, Kei
|
|
|
32 |
S4 |
p. S297
|
artikel
|
| 93 |
MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody®-PD-L1×4-1BB (GEN1046) in advanced solid tumors
|
Melero, Ignacio
|
|
|
32 |
S4 |
p. S313
|
artikel
|
| 94 |
MO12-5 Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan
|
Kiguchi, Toru
|
|
|
32 |
S4 |
p. S304
|
artikel
|
| 95 |
MO20-2 Phase I study of BI 754091 plus BI 754111 in Asian patients with gastric/gastroesophageal junction or esophageal cancer
|
Oh, Do-Youn
|
|
|
32 |
S4 |
p. S310
|
artikel
|
| 96 |
MO10-6 Phase 1 study of retifanlimab (anti-PD-1) and INCB001158 (arginase inhibitor), alone or in combination, in solid tumors
|
Koyama, Takafumi
|
|
|
32 |
S4 |
p. S302
|
artikel
|
| 97 |
MO8-5 Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer
|
Matsuyama, Chihiro
|
|
|
32 |
S4 |
p. S300
|
artikel
|
| 98 |
MO3-1 Pneumonitis is common in patients with sequential nivolumab and cetuximab treatment
|
Arai, Makoto
|
|
|
32 |
S4 |
p. S295
|
artikel
|
| 99 |
MO2-2 Preclinical evaluation of androgen deprivation with JAK1/2 and PD-L1 inhibition in mouse Pten-deficient prostate cancer
|
Kura, Yurie
|
|
|
32 |
S4 |
p. S295
|
artikel
|
| 100 |
MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer
|
Inagaki, Lina
|
|
|
32 |
S4 |
p. S320
|
artikel
|
| 101 |
MO5-6 Prognostic factor in gastric cancer patients with patients who received nivolumab
|
Matsumoto, Toshihiko
|
|
|
32 |
S4 |
p. S299
|
artikel
|
| 102 |
MO30-2 Prognostic factors for non-small cell lung cancer patients with brain metastases (HOT 1701)
|
Ohhara, Yoshihito
|
|
|
32 |
S4 |
p. S317
|
artikel
|
| 103 |
MO3-2 Prognostic significance of metastatic sites in recurrent or metastatic squamous cell carcinoma of the head and neck
|
Nishimura, Ari
|
|
|
32 |
S4 |
p. S296
|
artikel
|
| 104 |
MO21-1 Prognostic value of pneumonitis after durvalumab in locally-advanced non-small cell lung cancer
|
Nishimura, Ari
|
|
|
32 |
S4 |
p. S311
|
artikel
|
| 105 |
MO9-1 Real-world data of multiple diagnostic biomarker testing for lung cancer patients in Japan
|
Yatabe, Yasushi
|
|
|
32 |
S4 |
p. S300
|
artikel
|
| 106 |
MO20-3 Real-world outcomes of surgery versus chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
|
Sawada, Kentaro
|
|
|
32 |
S4 |
p. S310
|
artikel
|
| 107 |
MO29-5 RELAY+: Exploratory study of RAM+GEF in untreated patients with EGFR M+ NSCLC: Updates on efficacy, safety and biomarker
|
Nishio, Makoto
|
|
|
32 |
S4 |
p. S317
|
artikel
|
| 108 |
MO16-3 Results of the first survey using EORTC QLQ INFO25 on information acquisition and satisfaction of lung cancer patients
|
Shimizu, Hidefumi
|
|
|
32 |
S4 |
p. S306
|
artikel
|
| 109 |
MO5-2 Retrospective study of nivolumab monotherapy for advanced esophageal squamous cell carcinoma
|
Mikuni, Hayato
|
|
|
32 |
S4 |
p. S298
|
artikel
|
| 110 |
MO27-2 Risk factors for metastasis in prostate cancer patients: A systematic review
|
Susanto, Billy
|
|
|
32 |
S4 |
p. S315
|
artikel
|
| 111 |
MO25-4 Safety and efficacy of the combination of platinum, pemetrexed, and pembrolizumab in chemo-naive patients with NSCLC
|
Oya, Yuko
|
|
|
32 |
S4 |
p. S314
|
artikel
|
| 112 |
MO29-6 Safety and tolerability of lazertinib and in combination with amivantamab in advanced EGFR-mutated Japanese NSCLC
|
Goto, Koichi
|
|
|
32 |
S4 |
p. S317
|
artikel
|
| 113 |
MO10-1 Safety of immune checkpoint inhibitors in patients with advanced malignancy complicated with rheumatoid arthritis
|
Kudo, Keita
|
|
|
32 |
S4 |
p. S301
|
artikel
|
| 114 |
MO8-2 Sarcopenia on overall survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
|
Marcella, Elizabeth
|
|
|
32 |
S4 |
p. S300
|
artikel
|
| 115 |
MO11-6 Scalp cooling on chemotherapy can escape from hair loss
|
Yamashita, Koji
|
|
|
32 |
S4 |
p. S303
|
artikel
|
| 116 |
MO22-6 Second-line systemic therapy in patients with recurrent or metastatic adenoid cystic carcinoma
|
Kadowaki, Shigenori
|
|
|
32 |
S4 |
p. S312
|
artikel
|
| 117 |
MO23-2 Significance of maintenance therapies in symptomatic multiple myeloma patients with HDT/ASCT
|
Nakaya, Aya
|
|
|
32 |
S4 |
p. S312
|
artikel
|
| 118 |
MO31-1 Surgical treatment for pulmonary oligometastases in the patients with pancreatic cancer who underwent pancreatectomy
|
Shingo, Maeda
|
|
|
32 |
S4 |
p. S318
|
artikel
|
| 119 |
MO11-3 Survival outcomes of different histological subtypes in breast cancer
|
Tan, Ryan
|
|
|
32 |
S4 |
p. S303
|
artikel
|
| 120 |
MO19-5 The association between prices and clinical benefit of approved drugs for solid tumors in Japan
|
Matsubara, Yuki
|
|
|
32 |
S4 |
p. S309
|
artikel
|
| 121 |
MO11-7 The decision of adjuvant treatment using OncotypeDX and outcome in early breast cancer patients
|
Ozaki, Yuri
|
|
|
32 |
S4 |
p. S304
|
artikel
|
| 122 |
MO10-4 The efficacy of pembrolizumab in patients with high-frequency microsatellite instability (MSI-H) solid tumors
|
Sugimoto, Naotoshi
|
|
|
32 |
S4 |
p. S302
|
artikel
|
| 123 |
MO33-5 The impact of chemotherapy for cancer patients with COVID-19 on severity and mortality outcomes: A meta-analysis
|
Hariyanto, Timotius I.
|
|
|
32 |
S4 |
p. S320
|
artikel
|
| 124 |
MO7-3 The impact of sarcopenia on overall survival in patients with ovarian cancer: A systematic review and meta-analysis
|
Tandiono, Jeannette
|
|
|
32 |
S4 |
p. S299
|
artikel
|
| 125 |
MO11-4 The impact of sarcopenia on survival among non-metastatic breast cancer patients: A systematic review
|
Chen, Sharon
|
|
|
32 |
S4 |
p. S303
|
artikel
|
| 126 |
MO38-1 The latest procedure of liver biopsy in the era of cancer genomic therapies; the single center retrospective analysis
|
Ozeki, Yusuke
|
|
|
32 |
S4 |
p. S323
|
artikel
|
| 127 |
MO18-6 The tumor suppression potential of RNA pseudouridine synthase family via microRNA regulation
|
Kurimoto, Ryota
|
|
|
32 |
S4 |
p. S308
|
artikel
|
| 128 |
MO23-3 Thrombopoietin mimetics in myelodysplastic syndromes patients: A meta-analytic synthesis of randomized controlled trials
|
Azharuddin, Md
|
|
|
32 |
S4 |
p. S313
|
artikel
|
| 129 |
MO33-1 Trends in chemotherapy at our hospital and department under the COVID-19 pandemic
|
Kageyama, Akihiko
|
|
|
32 |
S4 |
p. S320
|
artikel
|
| 130 |
MO30-5 Updated efficacy and safety of patritumab deruxtecan (HER3-DXd; U3-1402), a HER3 directed antibody drug conjugate, in EGFRm NSCLC
|
Hayashi, Hidetoshi
|
|
|
32 |
S4 |
p. S318
|
artikel
|
| 131 |
O12-1 A novel gene-prediction model, virtual sequencing with deep learning to predict gene alterations in colorectal cancer
|
Kotani, Daisuke
|
|
|
32 |
S4 |
p. S290
|
artikel
|
| 132 |
O3-1 A phase II study on the efficacy of nivolumab in patients with cancer of unknown primary (CUP) (NivoCUP)
|
Noguchi, Emi
|
|
|
32 |
S4 |
p. S286
|
artikel
|
| 133 |
O16-1 Association of self-perceived burden with symptoms among patients with cancer undergoing outpatient chemotherapy
|
Aoki, Miwa
|
|
|
32 |
S4 |
p. S292
|
artikel
|
| 134 |
O7-4 Clinical utility of multi-disciplinary expert panel discussion in precision cancer medicine
|
Ikeda, Sadakatsu
|
|
|
32 |
S4 |
p. S287
|
artikel
|
| 135 |
O9-2 Comprehensive gene mutation profiling of ctDNA in ovarian cancer and its pathological and prognostic impact
|
Noguchi, Tomoko
|
|
|
32 |
S4 |
p. S288
|
artikel
|
| 136 |
O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*
|
Shimizu, Toshio
|
|
|
32 |
S4 |
p. S285
|
artikel
|
| 137 |
O1-3 Defined lifestyle and germline factors predispose Asian populations to gastric cancer
|
Suzuki, Akihiro
|
|
|
32 |
S4 |
p. S285
|
artikel
|
| 138 |
O11-5 Durvalumab(D) ± tremelimumab(T) + platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN
|
Saito, Haruhiro
|
|
|
32 |
S4 |
p. S289
|
artikel
|
| 139 |
O14-3 End-of-life decision-making among the AYA cancer patients
|
Kubo, Emi
|
|
|
32 |
S4 |
p. S291
|
artikel
|
| 140 |
O3-4 Etoposide, doxorubicin, and cisplatin with mitotane in metastatic adrenocortical carcinoma in the National Cancer Center
|
Uchihara, Masaki
|
|
|
32 |
S4 |
p. S286
|
artikel
|
| 141 |
O14-2 Evaluation of comprehensive geriatric assessment in elderly patients with pancreaticobiliary cancer
|
Suzuki, Yukari
|
|
|
32 |
S4 |
p. S291
|
artikel
|
| 142 |
O5-5 Gemcitabine plus nab-paclitaxel for second-line therapy of pancreatic cancer: A phase II, single-arm, multicenter study
|
Huh, Gunn
|
|
|
32 |
S4 |
p. S287
|
artikel
|
| 143 |
O6-2 Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
|
Chua, Alfredo V.
|
|
|
32 |
S4 |
p. S287
|
artikel
|
| 144 |
O11-3 Phase 2 trial of atezolizumab with bevacizumab for patients with PD-L1 high non-Sq NSCLC (WJOG10718L/At Be Study)
|
Nakamura, Atsushi
|
|
|
32 |
S4 |
p. S289
|
artikel
|
| 145 |
O12-2 Predictive role of tumor location in 1st-line treatment of colorectal cancer: A multicenter retrospective study of JSCCR
|
Ito, Takahiko
|
|
|
32 |
S4 |
p. S290
|
artikel
|
| 146 |
O16-2 Prognostic impacts of change in skeletal muscle mass during neoadjuvant chemotherapy in patients with esophageal cancer
|
Harada, Tsuyoshi
|
|
|
32 |
S4 |
p. S292
|
artikel
|
| 147 |
O10-3 Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer
|
Wirth, Lori J.
|
|
|
32 |
S4 |
p. S289
|
artikel
|
| 148 |
O8-4 Siteless study for feasibility of electronic patient-reported outcome (ePRO) collection system in oncology
|
Kachi, Kenta
|
|
|
32 |
S4 |
p. S288
|
artikel
|
| 149 |
O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data
|
Hutchings, Martin
|
|
|
32 |
S4 |
p. S292
|
artikel
|
| 150 |
O1-4 Survival time of nivolumab treatment in advanced gastric cancer from real-world data of the DELIVER trial (JACCRO GC-08)
|
Ishiguro, Atsushi
|
|
|
32 |
S4 |
p. S285
|
artikel
|
| 151 |
O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)
|
Nowakowski, Grzegorz
|
|
|
32 |
S4 |
p. S293
|
artikel
|
| 152 |
O13-3 Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: Updated efficacy results from VISION cohort A
|
Sakai, Hiroshi
|
|
|
32 |
S4 |
p. S290
|
artikel
|
| 153 |
O13-4 Tepotinib safety in MET exon 14 (METex14) skipping NSCLC: Updated results from the VISION trial
|
Morise, Masahiro
|
|
|
32 |
S4 |
p. S291
|
artikel
|
| 154 |
O6-4 The effect of intravenous mannitol in combination with normal saline on the prevention of cisplatin-induced nephrotoxicity: A randomized, double-blind, placebo-controlled trial
|
Sainamthip, Panot
|
|
|
32 |
S4 |
p. S287
|
artikel
|
| 155 |
O9-1 Updated results of a phase 2 study of niraparib in heavily pretreated high-grade serous ovarian cancer patients in Japan
|
Takehara, Kazuhiro
|
|
|
32 |
S4 |
p. S288
|
artikel
|
| 156 |
O4-3 Utility of an artificial intelligence-curation system, QA Commons, for clinical sequencing: SCRUM-Japan MONSTAR-SCREEN
|
Horasawa, Satoshi
|
|
|
32 |
S4 |
p. S286
|
artikel
|
| 157 |
P17-9 Absolute white blood cell counts profile as metastatic predictive factors in premenopausal breast cancer
|
Sri Indrani Remitha, Ni Putu
|
|
|
32 |
S4 |
p. S339
|
artikel
|
| 158 |
P44-5 A case of advanced gastric cancer responding to S-1/CDDP chemotherapy, leading to a pathological complete response
|
Kawada, Junji
|
|
|
32 |
S4 |
p. S353
|
artikel
|
| 159 |
P46-2 A case of cancer-associated dermatomyositis diagnosed after curative therapy for esophageal and oropharyngeal cancers
|
Suzumori, Chisaki
|
|
|
32 |
S4 |
p. S354
|
artikel
|
| 160 |
P48-2 A case of MYH9-ROS1 fusion gene-positive pulmonary adenocarcinoma who responded to entrectinib
|
Tsuda, Takeshi
|
|
|
32 |
S4 |
p. S355
|
artikel
|
| 161 |
P56-7 A case of Nuclear protein in testis (NUT) midline carcinoma with response to Ewing sarcoma-based chemotherapy regimen
|
Nakatani, Yuki
|
|
|
32 |
S4 |
p. S360
|
artikel
|
| 162 |
P55-10 A case of peritoneal mesothelioma that recurred 27 years later
|
Obara, Yoko
|
|
|
32 |
S4 |
p. S359
|
artikel
|
| 163 |
P48-8 A case of primary lung cancer that led to the diagnosis of SMARCA4-deficient thoracic sarcoid tumor by oncogene panel testing
|
Iriguchi, Nana
|
|
|
32 |
S4 |
p. S355
|
artikel
|
| 164 |
P51-1 A case of recurrent breast cancer with liver metastasis successfully treated with multi-disciplinary
|
Nakayama, Yuko
|
|
|
32 |
S4 |
p. S357
|
artikel
|
| 165 |
P44-10 A case of recurrent gastric cancer as a carcinomatosa pericarditis long years after surgery
|
Yamada, Hideharu
|
|
|
32 |
S4 |
p. S354
|
artikel
|
| 166 |
P44-9 A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab
|
Takano, Yuko
|
|
|
32 |
S4 |
p. S354
|
artikel
|
| 167 |
P43-6 A case of unresectable colorectal cancer who could continue chemotherapy by hemodialysis for renal failure after FOLFOX
|
Osone, Katsuya
|
|
|
32 |
S4 |
p. S352
|
artikel
|
| 168 |
P50-7 A case of Waldenstrom macroglobulinemia with severe systemic myalgia after rituximab treatment
|
Fujii, Soichiro
|
|
|
32 |
S4 |
p. S356
|
artikel
|
| 169 |
P44-4 A case report of four patients received ramucirumab monotherapy as second-line treatment for advanced gastric cancer
|
Onodera, Kei
|
|
|
32 |
S4 |
p. S353
|
artikel
|
| 170 |
P36-8 Achievements and challenges in developing the in-house certified nurses for cancer pain management
|
Numata, Kikuko
|
|
|
32 |
S4 |
p. S351
|
artikel
|
| 171 |
P39-4 Activities report of a support program for cancer patients and their families at Jichi Medical University Hospital
|
Yamamoto, Rie
|
|
|
32 |
S4 |
p. S351
|
artikel
|
| 172 |
P53-2 A long-term response and metachronous tumor shrinkage in a recurrent renal cell carcinoma with nivolumab: A case report
|
Yanagihara, Takeshi
|
|
|
32 |
S4 |
p. S358
|
artikel
|
| 173 |
P29-4 An exploratory study of challenges to delivering palliative care from the time of cancer diagnosis
|
Suyama, Hisashi
|
|
|
32 |
S4 |
p. S347
|
artikel
|
| 174 |
P18-5 An in vitro study of ALA-based PDT efficacy on uterine sarcoma in hormonal supplemented microenvironment
|
Chu, Ellie S.M.
|
|
|
32 |
S4 |
p. S339
|
artikel
|
| 175 |
P58-7 Aortitis after the use of granulocyte colony stimulating factors: A case of right lower gingival carcinoma
|
Watanabe, Masaya
|
|
|
32 |
S4 |
p. S360
|
artikel
|
| 176 |
P57-4 A rare case of cutaneous lymphoma in a rural hospital in Indonesia
|
Widjaja, Devita
|
|
|
32 |
S4 |
p. S360
|
artikel
|
| 177 |
P4-3 A reevaluation of adjuvant chemotherapy for colon cancer in our department
|
Kobayashi, Kazuma
|
|
|
32 |
S4 |
p. S331
|
artikel
|
| 178 |
P13-8 A retrospective analysis on the prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders
|
Takahata, Takenori
|
|
|
32 |
S4 |
p. S336
|
artikel
|
| 179 |
P5-8 A retrospective study for the significance of second-line therapy for unresectable or recurrent biliary tract cancer
|
Kawamoto, Yasuyuki
|
|
|
32 |
S4 |
p. S333
|
artikel
|
| 180 |
P30-6 A retrospective study of antiemetic therapies to prevent carboplatin-induced nausea and vomiting in lung cancer
|
Uesugi, Akinori
|
|
|
32 |
S4 |
p. S349
|
artikel
|
| 181 |
P4-7 A review of adjuvant chemotherapy for rectal cancer in our department, focusing on one-year administration of S-1
|
Kobayashi, Kazuma
|
|
|
32 |
S4 |
p. S331
|
artikel
|
| 182 |
P54-6 A role of prostaglandins in tissue repair: Delayed skin wound healing by celecoxib and bevacizumab during herpes zoster
|
Hirakawa, Satoshi
|
|
|
32 |
S4 |
p. S359
|
artikel
|
| 183 |
P2-2 A study of EOX as adjuvant chemotherapy post D2 resection in Vietnamese patients with locally advanced gastric cancer
|
Hoang, Hang Thu
|
|
|
32 |
S4 |
p. S330
|
artikel
|
| 184 |
P49-9 Atezolizumab in combination with carboplatin and etoposide (CE) for small-cell lung cancer after failure to CE
|
Takeda, Takayuki
|
|
|
32 |
S4 |
p. S356
|
artikel
|
| 185 |
P43-9 A 10-year marathon, race against time: Challenges in management of metastatic colon cancer
|
Ooi, Po Lin
|
|
|
32 |
S4 |
p. S352
|
artikel
|
| 186 |
P12-7 A young woman with muco-epidermoid carcinoma of the lung
|
Islam, S.M.A.
|
|
|
32 |
S4 |
p. S335
|
artikel
|
| 187 |
P14-2 Bleeding association with survival of patients with acute promyelocytic leukemia: Systematic review
|
Antony, Andre
|
|
|
32 |
S4 |
p. S336
|
artikel
|
| 188 |
P55-7 Bronchial neuroendocrine tumor causing acromegaly – a rare occurrence
|
Shafiq, Waqas
|
|
|
32 |
S4 |
p. S359
|
artikel
|
| 189 |
P4-9 Characteristics of patients with colorectal cancer in Sanglah Hospital, Denpasar, Bali
|
Sari, Felicia Puspita
|
|
|
32 |
S4 |
p. S332
|
artikel
|
| 190 |
P20-10 Chemical neurolysis for refractory head and neck cancer-related pain
|
Nasir, Khawaja S.
|
|
|
32 |
S4 |
p. S340
|
artikel
|
| 191 |
P28-10 Cisplatin induces DNA damage associated with cell cycle arrest and apoptosis in PC9 cells
|
Mohiuddin, Md
|
|
|
32 |
S4 |
p. S346
|
artikel
|
| 192 |
P21-7 Clinical cases of papillary thyroid and parathyroid carcinomas
|
Romanchishen, Anatoly
|
|
|
32 |
S4 |
p. S340
|
artikel
|
| 193 |
P30-3 Clinical experience of tumour lysis syndrome in patients with extensive disease small cell lung cancer
|
Kawamoto, Megumi
|
|
|
32 |
S4 |
p. S348
|
artikel
|
| 194 |
P33-1 Clinical feasibility of approved multigene panels in a Japanese local cancer accredited hospital
|
Tokudome, Nahomi
|
|
|
32 |
S4 |
p. S350
|
artikel
|
| 195 |
P17-8 Clinical impact of next-generation sequencing in patients with breast cancer: A single institute study
|
Nozawa, Kazuki
|
|
|
32 |
S4 |
p. S338
|
artikel
|
| 196 |
P31-7 Clinical outcomes of cerebral infarction associated with Trousseau’s syndrome in advanced pancreatic cancer patients
|
Oguri, Tomoyo
|
|
|
32 |
S4 |
p. S350
|
artikel
|
| 197 |
P1-3 Clinical profile and treatment outcomes of esophageal cancer patients treated with nivolumab: A real world data
|
Morita, Ryuichi
|
|
|
32 |
S4 |
p. S328
|
artikel
|
| 198 |
P18-2 Clinical usefulness of universal screening for Lynch syndrome in gynecological cancer of a single-center investigation
|
Ando, Yukiko
|
|
|
32 |
S4 |
p. S339
|
artikel
|
| 199 |
P4-13 cMET promotes metastasis and epithelial-mesenchymal transition in colorectal carcinoma via repressing RKIP
|
Liu, Jianhua
|
|
|
32 |
S4 |
p. S332
|
artikel
|
| 200 |
P22-3 Comparison of diagnostic characteristics between sentinel-node biopsy (SNB) and SNB with lymph node sampling in patients with oral tongue cancer cT1-2NOMO
|
Kotov, Maxim
|
|
|
32 |
S4 |
p. S341
|
artikel
|
| 201 |
P2-4 Comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as 2nd-line treatment for gastric cancer
|
Tsuji, Kunihiro
|
|
|
32 |
S4 |
p. S330
|
artikel
|
| 202 |
P20-2 Comparison of triweekly cisplatin regimens in adjuvant chemoradiotherapy for locally advanced head and neck cancer
|
Fujiwara, Yu
|
|
|
32 |
S4 |
p. S340
|
artikel
|
| 203 |
PD3-2-2 Analysis of the real-world accessibility of cancer genomic profiling after approval of national health insurance
|
Suga, Junko
|
|
|
32 |
S4 |
p. S326
|
artikel
|
| 204 |
PD4-1-3 A result of questionnaire about COVID-19 and chemotherapy, for patients utilizing outpatient chemotherapy center
|
Shibata, Takashi
|
|
|
32 |
S4 |
p. S327
|
artikel
|
| 205 |
PD3-1-5 Evaluation of inter-assay variability of next-generation sequencing based gene panels
|
Nguyen, Quy Pham
|
|
|
32 |
S4 |
p. S326
|
artikel
|
| 206 |
PD1-1-5 Frequency of immune-related adverse events of immune-checkpoint inhibitors for non-small cell lung cancer in our single institution
|
Chikamori, Kenichi
|
|
|
32 |
S4 |
p. S325
|
artikel
|
| 207 |
PD1-1-1 Phase Ib study of BI 836880 (VEGF/Ang2 nanobody®) plus ezabenlimab (BI 754091, anti-PD-1 antibody) in patients with solid tumors
|
Girard, Nicolas
|
|
|
32 |
S4 |
p. S325
|
artikel
|
| 208 |
PD1-2-5 Survival of heart versus cancer-specific death patients in the immunotherapy era
|
Safi, Mohammed
|
|
|
32 |
S4 |
p. S325
|
artikel
|
| 209 |
PD3-2-3 The short-time results of the OncoGuide NCC Oncopanel System for use in cancer genome profiling at a single institute
|
Tominaga, Shusei
|
|
|
32 |
S4 |
p. S326
|
artikel
|
| 210 |
PD3-1-3 Utility and role of multigene panel tests for patients with cancer: Retrospective data from a single institution
|
Hirasawa, Yuya
|
|
|
32 |
S4 |
p. S326
|
artikel
|
| 211 |
P25-6 Dynamic alteration of peripheral immune cells in patients with NSCLC received anti-PD-1 therapy and clinical efficacy
|
Yoshimura, Naruo
|
|
|
32 |
S4 |
p. S344
|
artikel
|
| 212 |
P28-7 Effects of pemetrexed disodium heptahydrate on apoptosis and cell cycle arrest in PC9 cells
|
Mohiuddin, Md
|
|
|
32 |
S4 |
p. S346
|
artikel
|
| 213 |
P4-2 Efficacy and eligibility predictors of trifluridine/tipiracil biweekly regimen in advanced colorectal cancer
|
Sanomachi, Tomomi
|
|
|
32 |
S4 |
p. S331
|
artikel
|
| 214 |
P11-7 Efficacy of afatinib following osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
|
Tamura, Tomohiro
|
|
|
32 |
S4 |
p. S335
|
artikel
|
| 215 |
P31-6 Efficacy of cardioprotective agents in preventing anthracycline-induced cardiotoxicity: A systematic review
|
Heriyanto, Rivaldo Steven
|
|
|
32 |
S4 |
p. S349
|
artikel
|
| 216 |
P25-4 Efficacy predictors of preoperative CRT and consolidation nivolumab in patients with locally advanced rectal cancer
|
Inamori, Koji
|
|
|
32 |
S4 |
p. S343
|
artikel
|
| 217 |
P55-6 Encorafenib for Erdheim-Chester disease harboring the BRAFV600E mutation
|
Wada, Fumiya
|
|
|
32 |
S4 |
p. S359
|
artikel
|
| 218 |
P20-1 Enhanced Foslip® photodynamic therapy anti-tumor effect in nasopharyngeal carcinoma via fractionated light irradiation
|
Wu, Ricky W.K.
|
|
|
32 |
S4 |
p. S339
|
artikel
|
| 219 |
P32-5 Eosinophilia predicted longer survival for solid tumor cancer patients treated with anti-PD-1 monoclonal antibody
|
Suzuki, Kazuhito
|
|
|
32 |
S4 |
p. S350
|
artikel
|
| 220 |
P28-3 Epithelial-mesenchymal transition changes mitochondrial oxidative phosphorylation in the lung adenocarcinoma cells
|
Takegahara, Kyoshiro
|
|
|
32 |
S4 |
p. S345
|
artikel
|
| 221 |
P22-7 Evaluate the effect of nasopharyngeal carcinoma 3D spheroid cell density on Hexyl-ALA induced PpIX accumulation
|
Wu, Ricky W.K.
|
|
|
32 |
S4 |
p. S341
|
artikel
|
| 222 |
P51-3 Examination of CARG toxicity scores in palbociclib therapy for elderly patients with breast cancer
|
Amioka, Ai
|
|
|
32 |
S4 |
p. S357
|
artikel
|
| 223 |
P30-2 Examination of improvement mechanism by minocycline application for skin disorders caused by afatinib
|
Sano, Kazumi
|
|
|
32 |
S4 |
p. S348
|
artikel
|
| 224 |
P17-1 Examination of predictors for therapeutic effect in 68 patients receiving palbociclib at our hospital
|
Higuchi, Toru
|
|
|
32 |
S4 |
p. S338
|
artikel
|
| 225 |
P15-9 Factors correlated to muscle strength in breast cancer patients before chemotherapy
|
Halim, Devina A.
|
|
|
32 |
S4 |
p. S337
|
artikel
|
| 226 |
P1-11 Four cases of definitive chemoradiotherapy with docetaxel/cisplatin/fluorouracil for advanced cervical esophageal cancer
|
Watanabe, Akinori
|
|
|
32 |
S4 |
p. S329
|
artikel
|
| 227 |
P42-4 Four cases of MSI-High solid tumors treated with pembrolizumab: Single institution experience
|
Inagaki, Takashi
|
|
|
32 |
S4 |
p. S352
|
artikel
|
| 228 |
P27-8 Genetic panel testing by liquid biopsy in our hospital
|
Matsumoto, Masahiro
|
|
|
32 |
S4 |
p. S345
|
artikel
|
| 229 |
P52-9 Hard diagnosis and treatment in a patient with HER-2 and TTF-1 positive adenocarcinoma
|
Nakayama, Hirofumi
|
|
|
32 |
S4 |
p. S357
|
artikel
|
| 230 |
P25-10 High sensitive troponin-I can be an effective predictive marker for drug-induced myocardial injury
|
Kobayashi, Yuka
|
|
|
32 |
S4 |
p. S344
|
artikel
|
| 231 |
P28-6 IL-6, IL-8, and VEGF secreted by PC9 and PC9-MET cells may impair the function of NK cells
|
Mohiuddin, Md
|
|
|
32 |
S4 |
p. S345
|
artikel
|
| 232 |
P10-7 Immunological and nutritional predictors for first-line chemoimmunotherapy in advanced non-small cell lung cancer
|
Takeda, Takayuki
|
|
|
32 |
S4 |
p. S334
|
artikel
|
| 233 |
P36-7 Importance of checking tinea infections before tyrosine kinase inhibitor treatment
|
Tahara, Yukie
|
|
|
32 |
S4 |
p. S351
|
artikel
|
| 234 |
PIN-1 Advanced epidemiological research for heated tobacco products in Japan
|
Tabuchi, Takahiro
|
|
|
32 |
S4 |
p. S282
|
artikel
|
| 235 |
P1-13 Indicative microorganisms associated with the progression of esophageal squamous cell carcinoma (ESCC) in China
|
Li, Minjuan
|
|
|
32 |
S4 |
p. S329
|
artikel
|
| 236 |
PIN-2 SDGs, ethical consumption, and promotion of smoking cessation
|
Kawano, Tetsuya
|
|
|
32 |
S4 |
p. S282
|
artikel
|
| 237 |
P23-9 Insulinoma; a single center case series
|
Shafiq, Waqas
|
|
|
32 |
S4 |
p. S343
|
artikel
|
| 238 |
P22-9 Intraoperative spinal accessory nerve monitoring during modified radical neck dissections in thyroid cancer patients
|
Vabalayte, Kristina
|
|
|
32 |
S4 |
p. S341
|
artikel
|
| 239 |
P37-7 Investigation of discarded anticancer agents after preparation in Nagoya Memorial Hospital
|
Hibi, Satoshi
|
|
|
32 |
S4 |
p. S351
|
artikel
|
| 240 |
P26-1 Investigation of the two chlorin-e6 based photosensitizers mediated Photodynamic Therapy (PDT) in human lymphocytes
|
Chu, Ellie S.M.
|
|
|
32 |
S4 |
p. S344
|
artikel
|
| 241 |
P3-11 Involvement of Helicobacter pylori with gastric MALT lymphoma among adults: A systematic review
|
Sutanto, Mario
|
|
|
32 |
S4 |
p. S331
|
artikel
|
| 242 |
P3-8 Lipocalin-2 expression might be a novel biomarker for patients with scirrhous-type gastric cancer
|
Nishimura, Sadaaki
|
|
|
32 |
S4 |
p. S330
|
artikel
|
| 243 |
P46-3 Long-term survival of patient with locally advanced and unresectable pancreatic cancer and myelodysplastic syndromes
|
Inoue, Masako
|
|
|
32 |
S4 |
p. S354
|
artikel
|
| 244 |
P16-3 Maintenance therapy in HER2 and hormone receptor-positive breast cancer
|
Bao, Shengnan
|
|
|
32 |
S4 |
p. S337
|
artikel
|
| 245 |
P53-4 Metastatic prostate cancer mimicking a rectal cancer: A case report
|
Chua, Alfredo V.
|
|
|
32 |
S4 |
p. S358
|
artikel
|
| 246 |
P54-5 Metastatic spinal cord compression caused by recurrent carcinoma ex pleomorphic adenoma of the parotid gland
|
Ando, Mark M.
|
|
|
32 |
S4 |
p. S358
|
artikel
|
| 247 |
P22-10 Modified radical neck dissections in different ages thyroid cancer patients
|
Romanchishen, Anatoly
|
|
|
32 |
S4 |
p. S342
|
artikel
|
| 248 |
P23-8 Multiple endocrine neoplasia type 2a syndrome: A tertiary care center experience in Pakistan
|
Azmat, Umal
|
|
|
32 |
S4 |
p. S343
|
artikel
|
| 249 |
P50-4 Neurogenic shock caused by CNS relapse of DLBCL
|
Maruta, Masaki
|
|
|
32 |
S4 |
p. S356
|
artikel
|
| 250 |
P29-5 Observation on the clinical efficacy of plant-extracted compound for brain metastatic tumor after failure with multi-line therapy
|
Pu, Rong
|
|
|
32 |
S4 |
p. S348
|
artikel
|
| 251 |
P6-6 Optimal dose intensity in the first 4 weeks during nab-PTX plus GEM for elderly patients with advanced pancreatic cancer
|
Iede, Kiyotsugu
|
|
|
32 |
S4 |
p. S333
|
artikel
|
| 252 |
Poster
|
|
|
|
32 |
S4 |
p. I
|
artikel
|
| 253 |
P13-3 Outcomes and cost effectiveness of treatment of diffuse large B cell non-Hodgkin’s lymphoma with gemcitabine based second salvage chemotherapy
|
Jhatial, Mussadique Ali
|
|
|
32 |
S4 |
p. S335
|
artikel
|
| 254 |
P8-7 Overall survival outcome of an early stage non-small cell lung cancer in stereotactic radiosurgery: Systematic review
|
Siregar, Axel Sebastian
|
|
|
32 |
S4 |
p. S334
|
artikel
|
| 255 |
P28-8 Paclitaxel inhibits the proliferation of PC9 cells through cell cycle arrest and apoptosis
|
Mohiuddin, Md
|
|
|
32 |
S4 |
p. S346
|
artikel
|
| 256 |
P28-9 Paclitaxel suppresses c-myc signaling pathway to induce apoptosis in PC9 cells
|
Mohiuddin, Md
|
|
|
32 |
S4 |
p. S346
|
artikel
|
| 257 |
P26-6 Pharmacokinetic advantage of HIPEC with cisplatin over systemic administration of cisplatin
|
Kireeva, Galina S.
|
|
|
32 |
S4 |
p. S345
|
artikel
|
| 258 |
P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer
|
Oh, Do-Youn
|
|
|
32 |
S4 |
p. S333
|
artikel
|
| 259 |
P34-1 Pilot study learning needs of palliative care team who care for cancer patients undergoing therapeutic for new cancer agents
|
Nakamura, Masako
|
|
|
32 |
S4 |
p. S350-S351
|
artikel
|
| 260 |
P9-4 Polypharmacy as a prognostic factor in older patients with advanced NSCLC
|
Matsuo, Takuma
|
|
|
32 |
S4 |
p. S334
|
artikel
|
| 261 |
P22-8 Possible targeted therapies in nasopharyngeal carcinoma
|
Chen, Jo-Pai
|
|
|
32 |
S4 |
p. S341
|
artikel
|
| 262 |
P58-3 Practice of oncogene panel testing at regional core hospitals – about the role of a pharmacist
|
Tsuji, Shunsuke
|
|
|
32 |
S4 |
p. S360
|
artikel
|
| 263 |
P15-3 Practices of breast self-examination among female residents in Tangail city, Bangladesh: A cross sectional study
|
Khatun, Mahmuda
|
|
|
32 |
S4 |
p. S336-S337
|
artikel
|
| 264 |
P1-6 Preoperative docetaxel, cisplatin, and 5-FU for resectable esophagogastric junction adenocarcinoma: Retrospective study
|
Hirose, Toshiharu
|
|
|
32 |
S4 |
p. S329
|
artikel
|
| 265 |
P22-11 Prevalence and risk factors for pre-treatment pain in oral cancer; a retrospective analysis
|
Nasir, Khawaja S.
|
|
|
32 |
S4 |
p. S342
|
artikel
|
| 266 |
P30-10 Prevention of chemotherapy-induced peripheral neuropathy by compression therapy
|
Kawaguchi, Nobuko
|
|
|
32 |
S4 |
p. S349
|
artikel
|
| 267 |
P8-3 Prognostic factors for nivolumab monotherapy in postoperative recurrence of non-small cell lung cancer
|
Inoue, Takashi
|
|
|
32 |
S4 |
p. S334
|
artikel
|
| 268 |
P15-10 Relationship between Tumor Infiltrating Lymphocytes and clinicopathological factors in luminal type breast cancer
|
Ayu Stiti Sadvika, I Gusti
|
|
|
32 |
S4 |
p. S337
|
artikel
|
| 269 |
P52-8 Resistant hypercalcemia of malignancy: A management conundrum
|
Choy, Kay Hau
|
|
|
32 |
S4 |
p. S357
|
artikel
|
| 270 |
P23-5 Retrospective analysis for chemotherapy in patients with digestive NEC
|
Terasawa, Hiroyuki
|
|
|
32 |
S4 |
p. S342
|
artikel
|
| 271 |
P4-11 Retrospective analysis of CARG toxicity score in older adults with advanced solid tumor
|
Hanamura, Fumiyasu
|
|
|
32 |
S4 |
p. S332
|
artikel
|
| 272 |
P1-9 Retrospective analysis of the efficacy and safety of FOLFOX in patients with esophageal cancer
|
Sukeno, Koshi
|
|
|
32 |
S4 |
p. S329
|
artikel
|
| 273 |
P1-5 Retrospective analysis of the efficacy and safety of nivolumab in patients with treatment-refractory esophageal cancer
|
Kobayashi, Toshiaki
|
|
|
32 |
S4 |
p. S328
|
artikel
|
| 274 |
P15-2 Risk factors and barriers of early breast cancer diagnosis and treatment outcome in Bangladesh
|
Al Mamun Khan, Abdullah
|
|
|
32 |
S4 |
p. S336
|
artikel
|
| 275 |
P1-2 Safety and efficacy of nivolumab therapy in patients with advanced esophageal squamous cell carcinoma
|
Shimada, Seitaro
|
|
|
32 |
S4 |
p. S328
|
artikel
|
| 276 |
P53-5 Severe hypercalcemia in renal cell carcinoma: The diverse manifestations of genitourinary malignancies
|
Choy, Kay Hau
|
|
|
32 |
S4 |
p. S358
|
artikel
|
| 277 |
PS3-2 Genomic characterization of circulating tumor DNA in advanced genitourinary cancer patients SCRUM-Japan MONSTAR SCREEN
|
Nonomura, Norio
|
|
|
32 |
S4 |
p. S284
|
artikel
|
| 278 |
P16-5 Single institute experience of treatment for metastatic HER2 positive breast cancer patients with trastuzumab deruxtecan
|
Kojima, Yasuyuki
|
|
|
32 |
S4 |
p. S338
|
artikel
|
| 279 |
PS1-2 Pembrolizumab vs chemotherapy for MSI-high/dMMR metastatic colorectal cancer: Asia subgroup of phase 3 KEYNOTE-177
|
Yoshino, Takayuki
|
|
|
32 |
S4 |
p. S284
|
artikel
|
| 280 |
PS3-5 Phase III study of palonosetron for preventing chemotherapy-induced nausea and vomiting in pediatric patients
|
Koga, Yuhki
|
|
|
32 |
S4 |
p. S284
|
artikel
|
| 281 |
PSY7-3 Adjuvant, conversion, and neoadjuvant therapy for biliary tract cancer
|
Hatano, Etsuro
|
|
|
32 |
S4 |
p. S244
|
artikel
|
| 282 |
PSY3-4 AI for practice
|
Lee Kiang Chua, Melvin
|
|
|
32 |
S4 |
p. S241
|
artikel
|
| 283 |
PSY3-3 AI for precision oncology
|
Muto, Manabu
|
|
|
32 |
S4 |
p. S241
|
artikel
|
| 284 |
PSY3-2 Artificial intelligence for cancer diagnosis and treatment
|
Suh, Brandon
|
|
|
32 |
S4 |
p. S241
|
artikel
|
| 285 |
PSY3-1 Artificial intelligence in oncology imaging
|
Sorensen, A. Gregory
|
|
|
32 |
S4 |
p. S241
|
artikel
|
| 286 |
PSY1-4 Cancer gene panel test for metastatic breast cancer: Current status and future perspectives
|
Tada, Hiroshi
|
|
|
32 |
S4 |
p. S240
|
artikel
|
| 287 |
PSY6-5 Challenges of gynecologic cancer research with Asian countries
|
Sudo, Kazuki
|
|
|
32 |
S4 |
p. S243
|
artikel
|
| 288 |
PSY4-4 Clinical oncology research environment in Malaysia: now and future
|
Yusof, Akhmal
|
|
|
32 |
S4 |
p. S242
|
artikel
|
| 289 |
PSY7-5 Current status and future perspectives in biliary tract cancer in Korea
|
Oh, Do-Youn
|
|
|
32 |
S4 |
p. S244
|
artikel
|
| 290 |
PSY7-4 Current status and future perspectives in biliary tract cancer in Singapore
|
Choo, Su Pin
|
|
|
32 |
S4 |
p. S244
|
artikel
|
| 291 |
PSY1-2 Expanding the reach of precision medicine in lung cancer
|
Johnson, Bruce E.
|
|
|
32 |
S4 |
p. S240
|
artikel
|
| 292 |
PSY6-3 International research collaboration in Singapore
|
Yap, Yoon-Sim
|
|
|
32 |
S4 |
p. S243
|
artikel
|
| 293 |
PSY4-2 PMDA’s efforts to promote regulatory convergence in Asia
|
Sato, Junko
|
|
|
32 |
S4 |
p. S242
|
artikel
|
| 294 |
PSY8-3 Precision medicine in biliary tract cancer
|
Bridgewater, John
|
|
|
32 |
S4 |
p. S245
|
artikel
|
| 295 |
PSY1-5 Precision medicine in gynecological cancer
|
Oda, Katsutoshi
|
|
|
32 |
S4 |
p. S240
|
artikel
|
| 296 |
PSY6-4 Regulatory aspect of regional collaboration for medical products development in Asia
|
Koga, Daisuke
|
|
|
32 |
S4 |
p. S243
|
artikel
|
| 297 |
PSY8-2 Search of biomarkers and creation of innovative methods required for precision medicine for gastric cancer
|
Shoji, Hirokazu
|
|
|
32 |
S4 |
p. S245
|
artikel
|
| 298 |
PSY1-1 The framework of cancer precision medicine in Japan
|
Yatabe, Yasushi
|
|
|
32 |
S4 |
p. S240
|
artikel
|
| 299 |
PSY6-1 The future perspective of Asian collaboration based on experience of investigator initiated global clinical trials (PENELOPE-B and PALLAS)
|
Iwata, Hiroji
|
|
|
32 |
S4 |
p. S243
|
artikel
|
| 300 |
P31-2 The characteristics of depression with the PHQ-9 in cancer patients at K hospital in Vietnam
|
Do, Mai
|
|
|
32 |
S4 |
p. S349
|
artikel
|
| 301 |
P25-9 The clinical courses of solid tumors with microsatellite instability-high (MSI-H)
|
Inagaki, Yuichiro
|
|
|
32 |
S4 |
p. S344
|
artikel
|
| 302 |
P28-11 The CRISPR-Cas13a gene-editing system underlies a potential therapeutic strategy for EML4-ALK-positive lung cancer cells
|
Saifullah, Saifullah
|
|
|
32 |
S4 |
p. S347
|
artikel
|
| 303 |
P13-6 The effectiveness of mogamulizumab against refractory angioimmunoblastic T cell lymphoma
|
Shimazu, Yutaka
|
|
|
32 |
S4 |
p. S335
|
artikel
|
| 304 |
P5-1 The efficacy of proton beam therapy in patients with hepatocellular carcinoma: A systematic review
|
Suciningtias, Marlyn
|
|
|
32 |
S4 |
p. S333
|
artikel
|
| 305 |
P3-1 The experience of nivolumab therapy in the patients with advanced and recurrence gastric cancer
|
Wada, Noriko
|
|
|
32 |
S4 |
p. S330
|
artikel
|
| 306 |
P4-10 The impact of neutrophil/lymphocyte ratio (NLR) on overall survival for patients with metastatic colorectal cancer
|
Harada, Kazuaki
|
|
|
32 |
S4 |
p. S332
|
artikel
|
| 307 |
P20-8 The impact of valproic acid on overall survival in patients with glioblastoma: A systematic review and meta-analysis
|
Jonatan, Charlotte A.
|
|
|
32 |
S4 |
p. S340
|
artikel
|
| 308 |
P30-1 The influence of thiamine declines on neuropsychiatric symptoms in patients with hematological cancer
|
Iimura, Yohei
|
|
|
32 |
S4 |
p. S348
|
artikel
|
| 309 |
P29-1 The results of the questionnaire survey of oral steroids for patients with cancer-related fatigue
|
Yamamura, Takahiro
|
|
|
32 |
S4 |
p. S347
|
artikel
|
| 310 |
P44-3 Thrombotic microangiopathy (TMA) after treatment with nivolumab in advanced gastric cancer
|
Sakamoto, Tomoyuki
|
|
|
32 |
S4 |
p. S353
|
artikel
|
| 311 |
P49-4 Thyroid dysfunction associated with immune checkpoint blockade: An emerging immune-related adverse event
|
Choy, Kay Hau
|
|
|
32 |
S4 |
p. S355
|
artikel
|
| 312 |
P41-4 Transition of the style of cooperation between hospitals and clinics in the terminal care of lung cancer and its meaning
|
Kato, Kan
|
|
|
32 |
S4 |
p. S352
|
artikel
|
| 313 |
P50-3 Treatment-free remission in e19a2 BCR-ABL1 chronic myeloid leukemia
|
Kajiguchi, Tomohiro
|
|
|
32 |
S4 |
p. S356
|
artikel
|
| 314 |
P23-4 Treatment outcomes of advanced gastrointestinal neuroendocrine carcinoma
|
Sugiyama, Keiji
|
|
|
32 |
S4 |
p. S342
|
artikel
|
| 315 |
P16-6 Tumor infiltrating lymphocyte and leukocyte ratios as metastatic predictor in HER2 positive luminal type breast cancer
|
Wikania Wira Wiguna, I Gede
|
|
|
32 |
S4 |
p. S338
|
artikel
|
| 316 |
P44-6 Twelve cases with metastatic gastric cancer were treated with chemo-immunotherapy
|
Ina, Kenji
|
|
|
32 |
S4 |
p. S353
|
artikel
|
| 317 |
P49-6 Two cases of unexpected cardiac tamponade as pseudoprogression due to immune checkpoint inhibitor in patients with advanced lung adenocarcinoma
|
Kodani, Masahiro
|
|
|
32 |
S4 |
p. S356
|
artikel
|
| 318 |
P49-5 Tyrosine kinase inhibitor-induced thyroid dysfunction in the era of precision cancer therapy
|
Choy, Kay Hau
|
|
|
32 |
S4 |
p. S355
|
artikel
|
| 319 |
SJS-2 Approaches to geriatric oncology in Japan
|
Mizutani, Tomonori
|
|
|
32 |
S4 |
p. S231
|
artikel
|
| 320 |
Society pages
|
|
|
|
32 |
S4 |
p. vii-viii
|
artikel
|
| 321 |
SP2-2 COVID-19 impact on the oncology practice in the USA
|
Ueno, Naoto T.
|
|
|
32 |
S4 |
p. S229
|
artikel
|
| 322 |
SP2-4 Impact of COVID-19 on clinical practice and research in oncology in Singapore – experience of the National University Cancer Institute
|
Soo, Ross A.
|
|
|
32 |
S4 |
p. S229
|
artikel
|
| 323 |
SP2-1 The impact of COVID-19 on cancer treatment in Japan; actual condition, countermeasure, and task
|
Sunakawa, Yu
|
|
|
32 |
S4 |
p. S229
|
artikel
|
| 324 |
SP2-3 The impact of the COVID-19 global pandemic on oncology drug development, clinical research and R&D in Japan
|
Shimizu, Toshio
|
|
|
32 |
S4 |
p. S229
|
artikel
|
| 325 |
SY24-2 Advance care planning through collaboration between physicians and nurses: Discussions to identify and advocate the intangible value of patients
|
Takenouchi, Sayaka
|
|
|
32 |
S4 |
p. S268
|
artikel
|
| 326 |
SY16-1 Advances in early breast cancer (EBC) care from the perspective of escalation and de-escalation
|
Curigliano, Giuseppe
|
|
|
32 |
S4 |
p. S260
|
artikel
|
| 327 |
SY3-4 Chemical coping and pseudo addiction in cancer patients
|
Yamaguchi, Shigeki
|
|
|
32 |
S4 |
p. S248
|
artikel
|
| 328 |
SY10-4 Clinical biomarkers to predict the efficacy of immune checkpoint inhibitors
|
Miura, Satoru
|
|
|
32 |
S4 |
p. S255
|
artikel
|
| 329 |
SY32-1 Clinical development of gene expression assay (oncotype DX) and future challenges in a ctDNA-based test era
|
Chao, Calvin
|
|
|
32 |
S4 |
p. S273
|
artikel
|
| 330 |
SY28-4 Clinical development of RET inhibitors for RET fusion positive non-small cell lung cancer (NSCLC)
|
Goto, Koichi
|
|
|
32 |
S4 |
p. S271
|
artikel
|
| 331 |
SY4-3 Combination immunotherapy in small-cell lung cancer
|
Kozuki, Toshiyuki
|
|
|
32 |
S4 |
p. S249
|
artikel
|
| 332 |
SY4-1 Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
|
Reck, Martin
|
|
|
32 |
S4 |
p. S249
|
artikel
|
| 333 |
SY23-4 Combination therapy with immune checkpoint inhibitor and targeted agents in metastatic TNBC and HR-positive breast cancer
|
Ozaki, Yukinori
|
|
|
32 |
S4 |
p. S267
|
artikel
|
| 334 |
SY21-5 Conversion surgery in unresectable pancreatic cancer – surgery perspectives
|
Takahashi, Hidenori
|
|
|
32 |
S4 |
p. S265
|
artikel
|
| 335 |
SY14-3 Current evidence and future perspectives on immunotherapy for cervical cancer
|
Hasegawa, Kosei
|
|
|
32 |
S4 |
p. S259
|
artikel
|
| 336 |
SY16-3 De-escalation in medical oncology
|
Hara, Fumikata
|
|
|
32 |
S4 |
p. S260
|
artikel
|
| 337 |
SY19-3 Delirium and family care for end-of-life cancer patients
|
Hayashi, Eriko
|
|
|
32 |
S4 |
p. S263
|
artikel
|
| 338 |
SY19-2 Delirium before the last days of life
|
Otani, Hiroyuki
|
|
|
32 |
S4 |
p. S263
|
artikel
|
| 339 |
SY18-3 Developing patient support in disasters situations
|
Egawa, Takashi
|
|
|
32 |
S4 |
p. S262
|
artikel
|
| 340 |
SY20-1 GCP renovation, its direction and recent trends
|
Osawa, Tomoko
|
|
|
32 |
S4 |
p. S264
|
artikel
|
| 341 |
SY17-3 Gut microbiome
|
Sunakawa, Yu
|
|
|
32 |
S4 |
p. S261
|
artikel
|
| 342 |
SY12-3 Hematopoietic transplantation for AML
|
Hwang, William YK.
|
|
|
32 |
S4 |
p. S257
|
artikel
|
| 343 |
SY14-1 Immune checkpoint blockade for ovarian cancer
|
Hamanishi, Junzo
|
|
|
32 |
S4 |
p. S259
|
artikel
|
| 344 |
SY4-2 Immune checkpoint inhibition in malignant pleural mesothelioma and thymic epithelial tumors
|
Park, Keunchil
|
|
|
32 |
S4 |
p. S249
|
artikel
|
| 345 |
SY4-4 Immune checkpoint inhibitors in perioperative treatment in lung cancer
|
Horinouchi, Hidehito
|
|
|
32 |
S4 |
p. S249
|
artikel
|
| 346 |
SY17-4 Immuno-oncology agents for advanced gastric cancer
|
Van Cutsem, Eric
|
|
|
32 |
S4 |
p. S261
|
artikel
|
| 347 |
SY1-2 Improving care and outcomes for cancer survivors: An Australian experience
|
Jefford, Michael
|
|
|
32 |
S4 |
p. S246
|
artikel
|
| 348 |
SY35-2 Industry views on health technology assessment
|
Aitoku, Yasuko
|
|
|
32 |
S4 |
p. S275
|
artikel
|
| 349 |
SY32-2 Innovative challenge on circulating tumor DNA (ctDNA) – tailored adjuvant treatment: CIRCULATE-Japan
|
Yoshino, Takayuki
|
|
|
32 |
S4 |
p. S273
|
artikel
|
| 350 |
SY12-4 Interim analysis of Hematologic Malignancies (HM)-SCREEN-Japan 01: a mutation profiling multicenter study of patients with AML
|
Miyamoto, Kenichi
|
|
|
32 |
S4 |
p. S257
|
artikel
|
| 351 |
SY9-1 Introduction 'Clinical questions on novel cancer immunotherapy'
|
Miura, Yuji
|
|
|
32 |
S4 |
p. S254
|
artikel
|
| 352 |
SY6-3 MRD monitoring in acute lymphoblastic leukemia treatment
|
Sanada, Masashi
|
|
|
32 |
S4 |
p. S251
|
artikel
|
| 353 |
SY31-3 Multiplexed immunohistochemistry for immune profiling
|
Sato, Eiichi
|
|
|
32 |
S4 |
p. S272
|
artikel
|
| 354 |
SY10-2 Neoantigenic potential of chromosomal rearrangements, and effects of filtering on tumor mutation burden estimates
|
Mansfield, Aaron S.
|
|
|
32 |
S4 |
p. S255
|
artikel
|
| 355 |
SY27-3 New attempts for cancer cachexia in pancreatic cancer
|
Mitsunaga, Shuichi
|
|
|
32 |
S4 |
p. S270
|
artikel
|
| 356 |
SY33-2 New perspectives on the treatment of thyroid cancer: novel drugs for medullary thyroid cancer
|
Wirth, Lori J.
|
|
|
32 |
S4 |
p. S274
|
artikel
|
| 357 |
SY28-1 New therapeutic strategies for EGFR mutant lung cancer
|
Janne, Pasi A.
|
|
|
32 |
S4 |
p. S271
|
artikel
|
| 358 |
SY33-3 Novel drugs for anaplastic thyroid cancer
|
Tahara, Makoto
|
|
|
32 |
S4 |
p. S274
|
artikel
|
| 359 |
SY11-2 Novel drugs including immune checkpoint inhibitors in combination with radiation therapy for head and neck cancer
|
Akimoto, Tetsuo
|
|
|
32 |
S4 |
p. S256
|
artikel
|
| 360 |
SY13-4 Novel targeted therapy development in triple-negative breast cancer
|
Ueno, Naoto T.
|
|
|
32 |
S4 |
p. S258
|
artikel
|
| 361 |
SY13-3 Novel therapeutic strategies for drug-tolerance in NSCLC with driver oncogenes
|
Yamada, Tadaaki
|
|
|
32 |
S4 |
p. S258
|
artikel
|
| 362 |
SY33-1 Novel treatment strategy for advanced differentiated thyroid cancer
|
Kiyota, Naomi
|
|
|
32 |
S4 |
p. S274
|
artikel
|
| 363 |
SY26-2 Optimal administration of molecular-targeted agents as secondary treatment for advanced hepatocellular carcinoma
|
Nakano, Masahito
|
|
|
32 |
S4 |
p. S269
|
artikel
|
| 364 |
SY1-1 Overview of strategies of cancer survivorship care in Japan
|
Watanabe, Kiyotaka
|
|
|
32 |
S4 |
p. S246
|
artikel
|
| 365 |
SY7-1 PARP inhibitor, anti-angiogenesis, or both? Best combination for first-line ovarian cancer treatments
|
Pujade-Lauraine, Eric
|
|
|
32 |
S4 |
p. S252
|
artikel
|
| 366 |
SY21-4 Perioperative treatments for borderline resectable pancreatic cancer
|
Takahashi, Shinichiro
|
|
|
32 |
S4 |
p. S265
|
artikel
|
| 367 |
SY21-3 Perioperative treatments for resectable pancreatic ductal adenocarcinoma
|
Satoi, Shohei
|
|
|
32 |
S4 |
p. S265
|
artikel
|
| 368 |
SY17-5 Potential biomarkers for immunotherapy of gastric cancer
|
Kawakami, Yutaka
|
|
|
32 |
S4 |
p. S261
|
artikel
|
| 369 |
SY37-1 Precision medicine in kidney cancer
|
Miura, Yuji
|
|
|
32 |
S4 |
p. S276
|
artikel
|
| 370 |
SY37-2 Precision medicine in prostate cancer
|
Fujita, Kazutoshi
|
|
|
32 |
S4 |
p. S276
|
artikel
|
| 371 |
SY37-3 Precision medicine in urothelial cancer
|
Kitamura, Hiroshi
|
|
|
32 |
S4 |
p. S276
|
artikel
|
| 372 |
SY16-5 Problems in clinical trials to evaluate de-escalation
|
Sakamaki, Kentaro
|
|
|
32 |
S4 |
p. S260
|
artikel
|
| 373 |
SY5-5 Real-world data in the era of immune checkpoint inhibitors
|
Narita, Yukiya
|
|
|
32 |
S4 |
p. S250
|
artikel
|
| 374 |
SY26-3 Systemic chemotherapy for intermediate-stage hepatocellular carcinoma
|
Ueshima, Kazuomi
|
|
|
32 |
S4 |
p. S269
|
artikel
|
| 375 |
SY10-1 The emerging role of cell-free DNA as a biomarker for cancer immunotherapy
|
Zhou, Caicun
|
|
|
32 |
S4 |
p. S255
|
artikel
|
| 376 |
SY2-5 The need for rehabilitation–rethinking the rehabilitation of older cancer patients
|
Ueno, Junya
|
|
|
32 |
S4 |
p. S247
|
artikel
|
| 377 |
SY8-1 The rationale of immunotherapy in colorectal cancer
|
Tabernero, Josep
|
|
|
32 |
S4 |
p. S253
|
artikel
|
| 378 |
SY22-5 Tumor-agnostic drug development and approval from regulatory authority's perspective
|
Nonaka, Takahiro
|
|
|
32 |
S4 |
p. S266
|
artikel
|
| 379 |
SY23-1 Understanding immune checkpoint inhibitors from a viewpoint of the cancer immunobiology
|
Sugie, Tomoharu
|
|
|
32 |
S4 |
p. S267
|
artikel
|
| 380 |
Table of Contents
|
|
|
|
32 |
S4 |
p. v-vi
|
artikel
|
| 381 |
Title Page
|
|
|
|
32 |
S4 |
p. iv
|
artikel
|
Tijdschrift beschrijving